TLR4 siRNA439 treatment caused a significant decrease (n = 4, ANOVA1w, P < 0.01, post hoc Dunnett testing) relative to the level in mismatch siRNA- and vehicle-treated bone cancer pain rats, and a significant decline compared to normal rats(P < 0.05) in the IBCP group. This evidence concerns the gene TLR4 and bone cancer.